Stocktoria
Arbutus Biopharma Corp ABUS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2010-11-13
Arbutus Biopharma Corp financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $14.1M | $6.2M | $18.1M | $39.0M | $11.0M |
| R&D expense | $25.2M | $54.0M | $73.7M | $84.4M | $65.5M |
| Operating income | -$38.2M | -$76.3M | -$78.1M | -$65.5M | -$73.5M |
| Interest expense | — | — | $459,000 | $1.7M | $2.9M |
| Income tax | $0 | $0 | $0 | $4.4M | $0 |
| Net income | -$33.5M | -$69.9M | -$72.8M | -$69.5M | -$76.2M |
| EPS (diluted) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 |
| Operating cash flow | -$39.6M | -$64.8M | -$85.9M | -$35.4M | -$67.5M |
| Free cash flow | -$39.6M | -$65.0M | -$86.9M | -$35.9M | -$68.3M |
| Cash & equivalents | $18.0M | $36.3M | $26.3M | $30.8M | $109.3M |
| Total assets | $94.6M | $131.7M | $144.4M | $195.4M | $204.5M |
| Total liabilities | $18.0M | $34.3M | $38.4M | $58.6M | $35.0M |
| Shareholders' equity | $76.6M | $97.4M | $106.0M | $136.9M | $169.4M |
Source: SEC EDGAR filings · CIK 0001447028 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.